In a recent LCGC peer exchange on the topic of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), Judith Hey-Hadavi , vice president of Medical Affairs at Worldwide Clinical Trials, and Nicole Snow Pharm D, BCSCP, CSP , clinical pharmacist at Olympia Pharmaceuticals, explored the evolving landscape of GLP-1 therapies
For micro-dosing purposes, compounded tirzepatide dosing starts at 1.25 mg once or twice weekly
More recently, in the OASIS 1 trial, participants using a 50 mg dose of oral semaglutide saw an impressive 15.1% average weight loss over 68 weeks, with 85% losing at least 5% of their body weight, and 34% losing 20% or more
He says they covered liability and insurance, with no mention of drug testing rules or the WADA prohibited list
Whats more, those who lost 5% or more of their body weight were more likely to have maintained the loss at a 15-year follow-up